Details for Patent: 12,409,184
Which drugs does patent 12,409,184 protect, and when does it expire?
Patent 12,409,184 protects AURLUMYN and is included in one NDA.
This patent has one patent family member in one country.
Summary for Patent: 12,409,184
| Title: | Iloprost compositions and formulations thereof |
| Abstract: | The present disclosure generally relates to treatment of systemic sclerosis with symptomatic Raynaud's Phenomenon by intravenous or subcutaneous administration of iloprost or a pharmaceutically acceptable salt thereof. |
| Inventor(s): | Wade W. BENTON, Kevin A. CHRISTAL |
| Assignee: | BTG International Inc |
| Application Number: | US19/018,702 |
|
Patent Claim Types: see list of patent claims | Composition; Formulation; Device; |
Drugs Protected by US Patent 12,409,184
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Btg Intl | AURLUMYN | iloprost | SOLUTION;INTRAVENOUS | 217933-001 | Feb 13, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,409,184
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| World Intellectual Property Organization (WIPO) | 2022032141 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
